Deborah Donnell

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Use of HIV Case Surveillance System to Design and Evaluate Site-Randomized Interventions in an HIV Prevention Study: HPTN 065
    DEBORAH J DONNELL
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Open AIDS J 6:122-30. 2012
  2. pmc Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
  3. pmc Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions
    Deborah Donnell
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Acquir Immune Defic Syndr 63:S130-4. 2013
  4. doi request reprint Successful discontinuation of the placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the partners PrEP study experience
    Patrick Ndase
    Departments of Global Health Medicine Epidemiology, University of Washington, Seattle, WA Centers for Disease Control and Prevention, Entebbe, Uganda Department of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi, Kenya Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA Infectious Disease Institute, Makerere University, Kampala, Uganda Kabwohe Clinical Research Center, Kabwohe, Uganda The AIDS Support Organization, Kampala, Uganda Department of Reproductive Health, Moi University, Eldoret, Kenya and Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA
    J Acquir Immune Defic Syndr 66:206-12. 2014
  5. pmc Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial
    Pamela M Murnane
    aDepartment of Epidemiology bDepartment of Global Health cDepartment of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Obstetrics and Gynaecology, University of Nairobi eDepartment of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi, Kenya fDivision of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda gDivision of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland hStatistical Center for HIV AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA iCenters for Disease Control and Prevention, Atlanta, Georgia, USA Members of the Partners PrEP Study Team listed at end of paper
    AIDS 27:2155-60. 2013
  6. pmc Hormonal contraceptive use and risk of HIV-1 disease progression
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, Washington 98104, USA
    AIDS 27:261-7. 2013
  7. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
  8. pmc Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis
    Kenneth K Mugwanya
    Department of Epidemiology, University of Washington, Seattle, WA, USA Department of Disease Control and Environmental Health, Makerere University, Kampala, Uganda
    Lancet Infect Dis 13:1021-8. 2013
  9. pmc A prospective study of the effect of pregnancy on CD4 counts and plasma HIV-1 RNA concentrations of antiretroviral-naive HIV-1-infected women
    Renee Heffron
    Department of Global Health, University of Washington, Seattle, WA Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya Wits Reproductive Health and HIV Institute WRHI, University of the Witwatersrand, Johannesburg, South Africa Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya Kenya Medical Research Institute, Nairobi, Kenya Department of Reproductive Health, Moi University, Eldoret, Kenya and Departments of Epidemiology and Medicine, University of Washington, Seattle, WA
    J Acquir Immune Defic Syndr 65:231-6. 2014
  10. pmc Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA, USA Department of Medicine, University of Washington, Seattle, WA, USA Department of Epidemiology, University of Washington, Seattle, WA, USA Electronic address
    Lancet Infect Dis 14:1055-64. 2014

Collaborators

Detail Information

Publications28

  1. pmc Use of HIV Case Surveillance System to Design and Evaluate Site-Randomized Interventions in an HIV Prevention Study: HPTN 065
    DEBORAH J DONNELL
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Open AIDS J 6:122-30. 2012
    ..To study implementation of strategy, population-level data are needed to monitor outcomes of these interventions. US HIV surveillance systems are a potential source of these data...
  2. pmc Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
    ..Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners...
  3. pmc Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions
    Deborah Donnell
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Acquir Immune Defic Syndr 63:S130-4. 2013
    ..This development is particularly complex because of inconsistency of efficacy results of FTC/TDF PrEP trials for HIV prevention...
  4. doi request reprint Successful discontinuation of the placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the partners PrEP study experience
    Patrick Ndase
    Departments of Global Health Medicine Epidemiology, University of Washington, Seattle, WA Centers for Disease Control and Prevention, Entebbe, Uganda Department of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi, Kenya Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA Infectious Disease Institute, Makerere University, Kampala, Uganda Kabwohe Clinical Research Center, Kabwohe, Uganda The AIDS Support Organization, Kampala, Uganda Department of Reproductive Health, Moi University, Eldoret, Kenya and Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA
    J Acquir Immune Defic Syndr 66:206-12. 2014
    ..Few biomedical HIV prevention trials have demonstrated HIV protection with novel interventions, and thus, communication of positive trial results and provision of an effective product have not been tested in many situations...
  5. pmc Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial
    Pamela M Murnane
    aDepartment of Epidemiology bDepartment of Global Health cDepartment of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Obstetrics and Gynaecology, University of Nairobi eDepartment of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi, Kenya fDivision of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda gDivision of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland hStatistical Center for HIV AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA iCenters for Disease Control and Prevention, Atlanta, Georgia, USA Members of the Partners PrEP Study Team listed at end of paper
    AIDS 27:2155-60. 2013
    ..One hypothesis proposed for these divergent results is that PrEP efficacy may be reduced in populations with higher HIV-1 incidence...
  6. pmc Hormonal contraceptive use and risk of HIV-1 disease progression
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, Washington 98104, USA
    AIDS 27:261-7. 2013
    ..For HIV-1-infected women, hormonal contraception prevents unintended pregnancy, excess maternal morbidity, and vertical HIV-1 transmission. Hormonal contraceptives are widely used but their effects on HIV-1 disease progression are unclear...
  7. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
    ..Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations...
  8. pmc Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis
    Kenneth K Mugwanya
    Department of Epidemiology, University of Washington, Seattle, WA, USA Department of Disease Control and Environmental Health, Makerere University, Kampala, Uganda
    Lancet Infect Dis 13:1021-8. 2013
    ..We studied whether the use of pre-exposure prophylaxis in HIV-uninfected men and women in HIV-serodiscordant couples was associated with increased sexual risk behaviour...
  9. pmc A prospective study of the effect of pregnancy on CD4 counts and plasma HIV-1 RNA concentrations of antiretroviral-naive HIV-1-infected women
    Renee Heffron
    Department of Global Health, University of Washington, Seattle, WA Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya Wits Reproductive Health and HIV Institute WRHI, University of the Witwatersrand, Johannesburg, South Africa Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya Kenya Medical Research Institute, Nairobi, Kenya Department of Reproductive Health, Moi University, Eldoret, Kenya and Departments of Epidemiology and Medicine, University of Washington, Seattle, WA
    J Acquir Immune Defic Syndr 65:231-6. 2014
    ....
  10. pmc Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA, USA Department of Medicine, University of Washington, Seattle, WA, USA Department of Epidemiology, University of Washington, Seattle, WA, USA Electronic address
    Lancet Infect Dis 14:1055-64. 2014
    ..We assessed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP...
  11. pmc Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception
    Pamela M Murnane
    aDepartment of Epidemiology bDepartment of Global Health, University of Washington, Seattle, Washington, USA cUniversity of Manitoba, Department of Internal Medicine, Winnipeg, Canada dCenter for Microbiology Research, Kenya Medical Research Institute eDepartment of Obstetrics and Gynaecology, University of Nairobi fDepartment of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi gDepartment of Reproductive Health, Moi University, Eldoret, Kenya hDepartment of Medicine, University of Washington iStatistical Center for HIV AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    AIDS 28:1825-30. 2014
    ..For women at risk of HIV-1, effective contraception and effective HIV-1 prevention are global priorities...
  12. pmc Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception
    Renee Heffron
    aDepartment of Global Health bDepartment of Medicine cDepartment of Epidemiology dPediatrics and Laboratory Medicine eDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA fCenter for Clinical Research, Kenya Medical Research Institute, Nairobi gDepartment of Reproductive Health, Moi University, Eldoret hDepartment of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital iCenter for Microbiology, Kenya Medical Research Institute, Nairobi, Kenya jVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA kDepartments of Medicine and Medical Microbiology, University of Manitoba, Winnipeg, Canada The Partners PrEP Study Team is listed in the Acknowledgements
    AIDS 28:2771-6. 2014
    ..To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1-infected partners use DMPA...
  13. pmc Quantifying ongoing HIV-1 exposure in HIV-1-serodiscordant couples to identify individuals with potential host resistance to HIV-1
    Romel D Mackelprang
    Department of Global Health, University of Washington, WA, USA
    J Infect Dis 206:1299-308. 2012
    ..We developed a novel approach for quantifying HIV-1 exposure to identify individuals remaining HIV-1 uninfected despite persistent high exposure...
  14. pmc Daily short message service surveys to measure sexual behavior and pre-exposure prophylaxis use among Kenyan men and women
    Kathryn Curran
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    AIDS Behav 17:2977-85. 2013
    ..87). PrEP adherence was high, missed doses were correlated with sexual abstinence, and unprotected sex was not associated with decreased PrEP adherence...
  15. pmc Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples
    Ying Qing Chen
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Contemp Clin Trials 33:1280-6. 2012
    ..Nevertheless, the durability of its long-term effectiveness is yet to be assessed. The HPTN 052 Study is still ongoing and will not complete till 2015...
  16. pmc Outside sexual partnerships and risk of HIV acquisition for HIV uninfected partners in African HIV serodiscordant partnerships
    Patrick Ndase
    Department of Global Health, University of Washington, Seattle, 98104, USA
    J Acquir Immune Defic Syndr 59:65-71. 2012
    ..As African countries scale-up couples HIV testing, little is known about sexual behaviors and HIV risk for HIV-uninfected partners in known HIV-serodiscordant relationships...
  17. pmc Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study
    Renee Heffron
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Lancet Infect Dis 12:19-26. 2012
    ..We aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners...
  18. pmc HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention
    Deborah Donnell
    Department of Global Health University of Washington and Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research Center, Seattle, WA Departments of Global Health Medicine Epidemiology, University of Washington, Seattle, WA Departments of Pharmacology and Molecular Sciences Medicine, Johns Hopkins University, Baltimore, MD Center for Global Health, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, MA Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda Department of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi and Department of Epidemiology, Johns Hopkins University, Baltimore, MD
    J Acquir Immune Defic Syndr 66:340-8. 2014
    ..Antiretroviral pre-exposure prophylaxis (PrEP) is a novel HIV prevention strategy for which adherence is a known determinant of efficacy. Blood concentrations of PrEP medications are one objective marker of adherence...
  19. pmc Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98195, USA
    Sci Transl Med 3:77ra29. 2011
    ..These data suggest that HIV-1 RNA in genital secretions could be used as a marker of HIV-1 sexual transmission risk...
  20. pmc An intervention to support HIV preexposure prophylaxis adherence in HIV-serodiscordant couples in Uganda
    Christina Psaros
    Department of Psychiatry, Massachusetts General Hospital Center, Boston, MA Harvard Medical School, Boston, MA Massachusetts General Hospital Center for Global Health, Boston, MA Infectious Disease Institute, Makerere University, Kampala, Uganda Department of Internal Medicine, University of Manitoba, Winnipeg, Canada Kabwohe Clinical Research Center, Kabwohe, Uganda Division of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, US Centers for Disease Control and Prevention, Entebbe, Uganda Department of Epidemiology, University of Washington, Seattle, WA Harvard School of Public Health, Boston, MA Infectious Diseases Institute, Makerere University College of Health Science, Kampala, Uganda Department of Global Health, University of Washington, Seattle, WA Fred Hutchinson Cancer Research Center, Seattle, WA Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA and Mbarara University of Science and Technology, Mbarara, Uganda
    J Acquir Immune Defic Syndr 66:522-9. 2014
    ..To date, there are no empirically supported PrEP adherence interventions. This article describes the process of developing a PrEP adherence intervention and presents results on its impact on adherence...
  21. pmc Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples
    Jared M Baeten
    University of Washington, WA, USA
    AIDS 24:737-44. 2010
    ....
  22. pmc Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals
    Laura Pattacini
    1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    AIDS Res Hum Retroviruses 29:1321-9. 2013
    ....
  23. pmc HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission: a multinational study among HIV-1 serodiscordant couples
    Erin Kahle
    aDepartment of Epidemiology bDepartment of Global Health cDepartment of Medicine dDepartment of Pediatrics eDepartment of Microbiology fDepartment of Laboratory Medicine, University of Washington gVaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA hKenya Medical Research Institute, Kisumu, Kenya iDepartment of Medicine, Indiana University, Indianapolis, Indiana, USA jDepartment of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi, Kenya kLondon School of Hygiene and Tropical Medicine, London, UK
    AIDS 28:235-43. 2014
    ..We compared the risk of HIV-1 transmission for subtype C versus non-C subtypes (A, D, G and recombinant forms) among heterosexual African HIV-1 serodiscordant couples...
  24. pmc Challenges in the design of HIV prevention trials in the United States
    Deborah Donnell
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 55:S136-40. 2010
    ..However, for interventions where efficacy is already established, conducting trials that test different implementation strategies in these populations could provide definitive evidence about how to achieve high levels of coverage...
  25. pmc Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial
    Deborah Donnell
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Ctr, Seattle, WA 98109, USA
    AIDS Behav 14:1182-9. 2010
    ....
  26. doi request reprint Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine-Naloxone: HIV Prevention Trials Network 058
    David S Metzger
    Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA and Treatment Research Institute, Philadelphia, PA Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD and Department of Pathology, University of Minnesota, Minneapolis, MN State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China Department of Family Medicine, Faculty of Medicine, Chiang Mai University Guangxi Centers for Disease Control and Prevention, Guangxi Center for HIV AIDS Prevention and Control, Nanning, China Xinjiang Autonomous Region Center for Disease Control and Prevention, Xinjiang, China Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD Department of Psychiatry, Yale School of Medicine, New Haven, CT Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD Division of AIDS, Pharmaceutical Affairs Branch, TX 77843
    J Acquir Immune Defic Syndr 68:554-61. 2015
    ..Injection opioid use plays a significant role in the transmission of HIV infection in many communities and several regions of the world. Access to evidence-based treatments for opioid use disorders is extremely limited...
  27. pmc Supporting research sites in resource-limited settings: challenges in implementing information technology infrastructure
    Christopher J Whalen
    Office of CyberInfrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD and Fred Hutchinson Cancer Research Center, Seattle, WA
    J Acquir Immune Defic Syndr 65:S44-9. 2014
    ..We describe examples of the practical and ethical/regulatory challenges raised by the use of these newer technologies for data collection in multisite clinical studies...
  28. pmc Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival
    Maxensia Owor
    Clinical Division, Makerere University Johns Hopkins University Research Collaboration, Kampala, Uganda Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Pediatrics and Child Health, Makerere University, Kampala, Uganda Science Facilitation Department, Family Health International, Durham, NC Department of Pathology, Johns Hopkins University, Baltimore, MD and Department of Epidemiology and Biostatistics, George Washington University School of Public Health and Health Services, Washington, DC
    J Acquir Immune Defic Syndr 64:464-71. 2013
    ..To describe 5-year growth, survival, and long-term safety among children exposed to nevirapine or zidovudine in an African perinatal prevention trial, HIVNET 012...